Trade Alert: The Director Of Ascelia Pharma AB (publ) (STO:ACE), Niels Mengel, Has Just Spent kr204k Buying 42% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Ascelia Pharma AB (publ) (STO:ACE) Director, Niels Mengel, recently bought kr204k worth of stock, for kr20.38 per share. While we're hesitant to get too excited about a purchase of that size, we do note it increased their holding by a solid 42%.
View our latest analysis for Ascelia Pharma
Ascelia Pharma Insider Transactions Over The Last Year
Chief Executive Officer Magnus Corfitzen made the biggest insider purchase in the last 12 months. That single transaction was for kr505k worth of shares at a price of kr20.60 each. That means that an insider was happy to buy shares at above the current price of kr19.88. Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
Happily, we note that in the last year insiders paid kr1.5m for 73.65k shares. But insiders sold 3400 shares worth kr64k. In total, Ascelia Pharma insiders bought more than they sold over the last year. You can see the insider transactions (by individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership of Ascelia Pharma
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 6.4% of Ascelia Pharma shares, worth about kr30m, according to our data. But they may have an indirect interest through a corporate structure that we haven't picked up on. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
What Might The Insider Transactions At Ascelia Pharma Tell Us?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Ascelia Pharma we think they are probably pretty confident of a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Ascelia Pharma. For instance, we've identified 4 warning signs for Ascelia Pharma (1 shouldn't be ignored) you should be aware of.
Of course Ascelia Pharma may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.
